PMID- 19332626
OWN - NLM
STAT- MEDLINE
DCOM- 20090619
LR  - 20221207
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 36
IP  - 5
DP  - 2009 May
TI  - Autoantibody and biopsy grading are associated with expression of ICAM-1, MMP-3, 
      and TRAIL in salivary gland mononuclear cells of Chinese patients with Sjogren's 
      syndrome.
PG  - 989-96
LID - 10.3899/jrheum.080733 [doi]
AB  - OBJECTIVE: Sjogren's syndrome (SS) is an inflammatory autoimmune disease. We 
      investigated important factors associated with the expression of 
      inflammation-related molecules in minor salivary gland (MSG) mononuclear cells in 
      patients with SS. METHODS: Thirty-four patients with SS with a MSG biopsy grading 
      of either grade III (10 patients) or grade IV (24 patients) were enrolled. The 
      age, sex, autoantibodies, cell infiltration, and intercellular adhesion 
      molecule-1 (ICAM-1), matrix metalloproteinase-3 (MMP-3), tumor necrosis 
      factor-related apoptosis-inducing ligand (TRAIL), or CXCR3 expression were also 
      analyzed. RESULTS: Ten of the 34 patients with SS were diagnosed with secondary 
      SS; in these patients, the diagnosis of rheumatoid arthritis was confirmed in 8 
      and systemic lupus erythematosus in 2. TRAIL and ICAM-1 were overexpressed in 
      patients with antinuclear antibodies (ANA) > 1:160, compared to those with titer 
      < 1:160 (45.1 +/- 4.4 vs 41.2 +/- 3.9, p = 0.021, and 15.2 +/- 5.7 vs 10.8 +/- 
      3.3, p = 0.018, respectively). Higher erythrocyte sedimentation rate (ESR; >OR= 
      20) was associated with higher TRAIL expression and CD20 cell infiltration in 
      contrast to lower ESR (< 20; p < 0.05). ICAM-1, TRAIL, and MMP-3 were expressed 
      more predominantly in anti-SSA-positive than in anti-SSA-negative patients with 
      SS. There was a significant difference in CD20 cell infiltration and MMP-3 
      expression between primary SS and secondary SS. Biopsy of a grade IV showed a 
      significantly increased expression of TRAIL (44.9 +/- 4.5 vs 40.8 +/- 3.6, p = 
      0.013) and MMP-3 (62.7 +/- 6.3 vs 54.4 +/- 7.3, p = 0.003) in mononuclear cells 
      as compared to those of grade III. CONCLUSION: In our study, pathologic grading 
      with a higher grade (grade IV) and the presence of SSA or a higher titer of ANA 
      were significantly associated with the overexpression of TRAIL, MMP-3, or ICAM-1 
      in the salivary gland mononuclear cells in patients with SS.
FAU - Chen, Wei-Sheng
AU  - Chen WS
AD  - Department of Medicine, Division of Allergy, Immunology and Rheumatology, Taipei 
      Veterans General Hospital and National Yang-Ming University School of Medicine, 
      Beitou District, Taipei, Taiwan.
FAU - Lin, Kuan-Chia
AU  - Lin KC
FAU - Chen, Chun-Hsiung
AU  - Chen CH
FAU - Liao, Hsien-Tzung
AU  - Liao HT
FAU - Wang, Hon-Pin
AU  - Wang HP
FAU - Li, Wing-Yin
AU  - Li WY
FAU - Lee, Hui-Ting
AU  - Lee HT
FAU - Tsai, Chang-Youh
AU  - Tsai CY
FAU - Chou, Chung-Tei
AU  - Chou CT
LA  - eng
PT  - Journal Article
DEP - 20090330
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Antibodies, Antinuclear)
RN  - 0 (Biomarkers)
RN  - 0 (TNF-Related Apoptosis-Inducing Ligand)
RN  - 0 (TNFSF10 protein, human)
RN  - 126547-89-5 (Intercellular Adhesion Molecule-1)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
EIN - J Rheumatol. 2009 Jun;36(6):1351
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Antinuclear/*blood
MH  - Asian People
MH  - Biomarkers/metabolism
MH  - Epithelial Cells/*metabolism/pathology
MH  - Female
MH  - Fluorescent Antibody Technique, Indirect
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Intercellular Adhesion Molecule-1/*metabolism
MH  - Male
MH  - Matrix Metalloproteinase 3/*metabolism
MH  - Middle Aged
MH  - Salivary Glands, Minor/immunology/*metabolism/pathology
MH  - Sjogren's Syndrome/immunology/*metabolism/pathology
MH  - TNF-Related Apoptosis-Inducing Ligand/*metabolism
MH  - Taiwan
MH  - Young Adult
EDAT- 2009/04/01 09:00
MHDA- 2009/06/20 09:00
CRDT- 2009/04/01 09:00
PHST- 2009/04/01 09:00 [entrez]
PHST- 2009/04/01 09:00 [pubmed]
PHST- 2009/06/20 09:00 [medline]
AID - jrheum.080733 [pii]
AID - 10.3899/jrheum.080733 [doi]
PST - ppublish
SO  - J Rheumatol. 2009 May;36(5):989-96. doi: 10.3899/jrheum.080733. Epub 2009 Mar 30.